中原 仁 (ナカハラ ジン)

NAKAHARA Jin

写真a

所属(所属キャンパス)

医学部 内科学教室(神経) Department of Neurology, Keio University School of Medicine (信濃町)

職名

教授

メールアドレス

メールアドレス

HP

外部リンク

プロフィール 【 表示 / 非表示

  • ・日本神経学会
      関東甲信越支部代表
      代議員
      英文誌編集委員会幹事
      将来構想委員会委員
      年次学術委員(第61回)
    ・日本内科学会
      評議員
    ・日本神経免疫学会
      理事
    ・日本神経治療学会
      評議員
    ・日本神経感染症学会
      評議員
    ・日本多発性硬化症ネットワーク
      理事
    ・環アジア多発性硬化症治療研究会議(PACTRIMS)
      中央委員会委員

教員からのメッセージ 【 表示 / 非表示

  • 神経内科領域のあらゆる疾患を対象に、先進的なトランスレーショナル・リサーチから在宅医療まで、手段を問わず患者の生命の質(quality of life)を改善させる治療の具現化に向けた研究を行っている。

その他の所属・職名 【 表示 / 非表示

  • 慶應義塾大学グローバルリサーチインスティテュート, 副所長

  • 慶應義塾大学病院脳卒中センター, センター長

経歴 【 表示 / 非表示

  • 2003年04月
    -
    2004年03月

    慶應義塾大学, COEプログラム(生命科学), 研究員

  • 2004年04月
    -
    2007年03月

    独立行政法人日本学術振興会, 特別研究員(DC1)

  • 2007年04月
    -
    2008年11月

    独立行政法人日本学術振興会, 特別研究員(PD)

  • 2008年12月
    -
    2013年03月

    慶應義塾大学, 医学部総合医科学研究センター, 特任講師

  • 2013年04月
    -
    2018年03月

    慶應義塾大学, 医学部内科学教室(神経), 助教

全件表示 >>

学歴 【 表示 / 非表示

  • 2003年03月

    慶應義塾, 医学部

    大学, 卒業

  • 2007年03月

    慶應義塾, 医学研究科, 生理系専攻

    大学院, 修了, 博士

学位 【 表示 / 非表示

  • 博士(医学), 慶應義塾, 課程, 2007年03月

免許・資格 【 表示 / 非表示

  • 医師免許証, 2003年05月

  • 日本医師会認定産業医, 2011年09月

  • 日本内科学会認定内科医, 2013年09月

  • 日本神経学会認定神経内科専門医, 2014年07月

  • 日本内科学会認定総合内科専門医, 2019年12月

 

研究分野 【 表示 / 非表示

  • 神経内科学

研究キーワード 【 表示 / 非表示

  • オリゴデンドロサイト

  • 多発性硬化症

  • 神経免疫学

  • 神経内科学

  • 視神経脊髄炎関連疾患

全件表示 >>

研究テーマ 【 表示 / 非表示

  • 神経治療学の拠点形成, 

    2018年
    -
    継続中

  • 多発性硬化症の臨床研究, 

    2011年
    -
    継続中

  • 中枢神経系髄鞘再生療法の開発, 

    1999年
    -
    継続中

 

著書 【 表示 / 非表示

  • Visualization of Myelin for the Diagnosis and Treatment Monitoring of Multiple Sclerosis

    Nakahara J., Advances in Experimental Medicine and Biology, 2019年

     概要を見る

    Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) affecting more than two million people worldwide. As the exact etiology of MS remains elusive, the diagnosis of MS is made by referring to the McDonald diagnostic criteria, which utilizes MRI as a tool to identify “demyelinated” MS lesions. In particular, hyperintense lesions on T2-weighted images (T2WI) or so-called “T2-lesions” are considered to represent demyelinated MS lesions. T2WI, however, lacks myelin specificity, and moreover, remyelination could not be depicted by the use of such modality. For the accurate diagnosis and treatment decision-making, or for the future development of remyelination therapeutics, imaging tools to visualize myelin-specific signals are mandatory. In this chapter, the current use and the limitation of imaging modalities in MS diagnosis and treatment will be reviewed, with the introduction of new imaging method, namely q-space Myelin Map (qMM), to be used for visualization of demyelination and remyelination in MS.

論文 【 表示 / 非表示

  • Meningitis caused by Listeria monocytogenes in a locally advanced cervical cancer patient with pyometra: A case report

    Matoba Y., Nishio H., Sekiguchi K., Uno S., Masuda K., Hiramatsu M., Takahashi M., Oishi M., Uwamino Y., Uchida S., Daté Y., Morisada T., Banno K., Nakahara J., Aoki D.

    Gynecologic Oncology Reports (Gynecologic Oncology Reports)  37 2021年08月

     概要を見る

    Locally advanced cervical cancer occasionally induces pyometra, but there have been no reports of meningitis where pyometra is the cause of infection. Here, we report a case of Listeria monocytogenes meningitis related to pyometra during concurrent chemoradiotherapy (CCRT) in a cervical cancer patient. The patient, a 77-year-old woman, was diagnosed with Stage IIB (FIGO 2018) cervical adenocarcinoma, and CCRT was initiated. Pyometra was exacerbated during CCRT, and after her first brachytherapy, she presented at our hospital with fever and decreased consciousness level. After admission to the Intensive Care Unit, the patient lost consciousness and experienced frequent seizures; tracheal intubation was required. Whole-body computed tomography revealed pyometra; therefore, transvaginal removal of the abscess was performed. Laboratory tests and vital signs indicated septic shock, and meropenem was administered. L. monocytogenes was detected in the abscess from the uterine cavity and the blood cultures on the third day of hospitalization. A lumbar puncture was performed on the same day to investigate whether the patient had meningitis. A FilmArray meningitis/encephalitis panel test of the spinal fluid revealed L. monocytogenes. After the diagnosis of meningitis with L. monocytogenes, ampicillin and gentamicin were started, and the blood test results gradually improved. Five months after the initial episode, her consciousness recovered, however she still received mechanical ventilatory support. L. monocytogenes infections can occur in patients undergoing chemotherapy, even without the use of steroids or immunosuppressive agents. In cases with pyometra, intrauterine manipulation can increase the risk of severe infection.

  • Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study

    Kira J.I., Nakahara J., Sazonov D.V., Kurosawa T., Tsumiyama I., Willi R., Zalesak M., Pingili R., Häring D.A., Ramanathan K., Kieseier B.C., Merschhemke M., Su W., Saida T.

    Multiple Sclerosis Journal (Multiple Sclerosis Journal)  2021年

    ISSN  13524585

     概要を見る

    Background: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, has been developed as a treatment for relapsing multiple sclerosis (RMS) which can be self-administered at home. Objective: To investigate the efficacy and safety of ofatumumab in RMS patients from Japan and Russia. Methods: APOLITOS included a 24-week, double-blind, placebo-controlled core-part followed by an open-label extension-part. Patients were randomized (2:1) to subcutaneous ofatumumab 20 mg or placebo. Primary outcome was the number of gadolinium-enhancing (Gd+) T1 lesions per scan over 24 weeks. Results: Sixty-four patients were randomized (ofatumumab, n = 43; placebo, n = 21). Primary endpoint was met; ofatumumab reduced Gd + T1 lesions versus placebo by 93.6% (p < 0.001) and the results were consistent across regions (Japan/Russia). Ofatumumab reduced annualized T2 lesion and relapse rate versus placebo by week 24. Both groups showed benefit from ofatumumab in the extension-part. Incidence of adverse events was lower with ofatumumab versus placebo (69.8% vs 81.0%); injection-related reactions were most common. No deaths, opportunistic infections, or malignancies were reported. Conclusion: Ofatumumab demonstrated superior efficacy versus placebo, with sustained effect through 48 weeks in RMS patients from Japan/Russia. Switching to ofatumumab after 24 weeks led to rapid radiological and clinical benefits. Safety findings were consistent with pivotal trials.

  • Mechanisms of myelin repair, MRI techniques and therapeutic opportunities in multiple sclerosis

    Sommer R.C., Hata J., Rimkus C.d.M., Klein da Costa B., Nakahara J., Sato D.K.

    Multiple Sclerosis and Related Disorders (Multiple Sclerosis and Related Disorders)  2021年

    ISSN  22110348

     概要を見る

    Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). The remyelination process requires the activation, migration and differentiation of oligodendrocyte progenitor cells (OPC) in demyelinated areas. The metabolic dysfunction in chronic demyelinating lesions impairs the activation of OPCs, the myelin debris clearance by microglia decreases with age, along with diminished secretion of factors promoting OPC differentiation. Conventional magnetic resonance imaging (MRI) sequences have limited ability to differentiate unmyelinated and remyelinated lesions. Advanced MRI sequences based on magnetization transfer ratio (MTR), myelin water fraction (MWF) and diffusion tensor imaging (DTI) have been used to evaluate remyelination in clinical trials. More recently, the q-space myelin map (qMM) has been used on experimental and exploratory clinical studies. The improvement of myelin-specific MRI sequences with high reliability and standardization among centers will allow a more accurate evaluation of new therapies to improve remyelination. These new remyelination promoting treatments alone or in combination with current options may reduce the risk of long-term disability in MS.

  • Painless thyroiditis presenting with headache

    Takizawa T., Kurihara I., Suzuki N., Nakahara J., Shibata M.

    Internal Medicine (Internal Medicine)  60 ( 16 ) 2693 - 2696 2021年

    ISSN  09182918

     概要を見る

    Although headache attributed to hypothyroidism is coded within The International Classification of Headache Disorders, 3rd edition, an association between headache and thyrotoxicosis (hyperthyroidism) is mentioned only in the appendix. Reports on relevant cases are too scarce to establish a causal relationship. A young man with a history of migraine with aura arrived at our headache clinic with a 10-day history of headache and weight loss. Brain MRI revealed normal findings. Blood tests revealed thyrotoxicosis. A test for thyroid-related antibodies was negative. Thus, the patient was diagnosed with painless thyroiditis. The patient's headache resolved as his thyroid hormone levels decreased. To the best of our knowledge, this is the first reported case of headache exaggerated by painless thyrotoxicosis.

  • Differential pial and penetrating arterial responses examined by optogenetic activation of astrocytes and neurons

    Hatakeyama N., Unekawa M., Murata J., Tomita Y., Suzuki N., Nakahara J., Takuwa H., Kanno I., Matsui K., Tanaka K.F., Masamoto K.

    Journal of Cerebral Blood Flow and Metabolism (Journal of Cerebral Blood Flow and Metabolism)  41 ( 10 ) 2676 - 2689 2021年

    ISSN  0271678X

     概要を見る

    A variety of brain cells participates in neurovascular coupling by transmitting and modulating vasoactive signals. The present study aimed to probe cell type-dependent cerebrovascular (i.e., pial and penetrating arterial) responses with optogenetics in the cortex of anesthetized mice. Two lines of the transgenic mice expressing a step function type of light-gated cation channel (channelrhodopsine-2; ChR2) in either cortical neurons (muscarinic acetylcholine receptors) or astrocytes (Mlc1-positive) were used in the experiments. Photo-activation of ChR2-expressing astrocytes resulted in a widespread increase in cerebral blood flow (CBF), extending to the nonstimulated periphery. In contrast, photo-activation of ChR2-expressing neurons led to a relatively localized increase in CBF. The differences in the spatial extent of the CBF responses are potentially explained by differences in the involvement of the vascular compartments. In vivo imaging of the cerebrovascular responses revealed that ChR2-expressing astrocyte activation led to the dilation of both pial and penetrating arteries, whereas ChR2-expressing neuron activation predominantly caused dilation of the penetrating arterioles. Pharmacological studies showed that cell type-specific signaling mechanisms participate in the optogenetically induced cerebrovascular responses. In conclusion, pial and penetrating arterial vasodilation were differentially evoked by ChR2-expressing astrocytes and neurons.

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

総説・解説等 【 表示 / 非表示

競争的資金等の研究課題 【 表示 / 非表示

  • ミエリンマップ法を用いた多発性硬化症における髄鞘病理の画像解析

    2018年04月
    -
    2023年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 中原 仁, 基盤研究(C), 補助金,  代表

  • 髄鞘を標的とした神経変性疾患・脊髄損傷に対する新規治療戦略に関する研究

    2013年04月
    -
    2016年03月

    文部科学省, 科学研究費補助金(文部科学省・日本学術振興会), 中原仁, 補助金,  代表

  • 髄鞘の可視化技術による多発性硬化症の病型分類に関する研究

    2013年04月
    -
    2016年03月

    文部科学省, 科学研究費補助金(文部科学省・日本学術振興会), 中原仁, 補助金,  代表

  • アストロサイトによるin vivoケトン体生合成機構の解明

    2010年04月
    -
    2013年03月

    文部科学省, 科学研究費補助金(文部科学省・日本学術振興会), 中原仁, 補助金,  代表

  • 内在性オリゴデンドロサイト前駆細胞の分化誘導を基盤とする中枢神経系髄鞘再生医薬の開発

    2009年04月
    -
    2012年03月

    独立行政法人医薬基盤研究所, 保健医療分野における基礎研究推進事業, 中原仁, 受託研究,  代表

全件表示 >>

知的財産権等 【 表示 / 非表示

  • Drug delivery system toward demyelinating lesion and biochemical marker of demyelinating lesions

    特願: 8252540  2012年08月 

    特許: 8252540  2012年08月

    特許, 共同

  • Medicinal compositions containing Fc receptor γ chain activator

    特願: 7901678  2011年03月 

    特許: 7901678  2011年03月

    特許, 共同

  • Fc受容体γ鎖活性化物質を含有する医薬組成物

    特願: 4214249  2008年11月 

    特許: 4214249  2008年11月

    特許, 共同

受賞 【 表示 / 非表示

  • Best Presentation賞

    2017年, Sendai Conference

  • MSJ-PACTRIMS investigator award

    2014年, Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS)

  • 優秀指導教官賞

    2014年, 日本内科学会

  • MSJ-PACTRIMS Investigator賞

    2014年, 環アジア多発性硬化症治療研究会議

  • 優秀指導教官賞

    2014年, 内科学サミット2014

全件表示 >>

 

担当授業科目 【 表示 / 非表示

  • 内科学(神経)講義

    2021年度

  • 内科学演習

    2021年度

  • 内科学実習

    2021年度

  • 内科学

    2021年度

  • 基礎臨床統合医学

    2021年度

全件表示 >>

 

所属学協会 【 表示 / 非表示

  • 日本内科学会

     
  • 日本神経学会

     
  • 日本神経免疫学会

     
  • 日本神経治療学会

     
  • 日本脳卒中学会

     

全件表示 >>